Rare Diseases Strategic Roundup: From Scientific Breakthroughs to Patient Access | Sep 16- Oct 12, 2026
Rare disease market trends signal a competitive shift toward demonstrable…
Cell and Gene Therapy Strategic Roundup | Sep 1 – Oct 6, 2026
Gene and cell therapy competition is shifting beyond efficacy. Durability,…
Basecamp Research $140M Series C: The Translation Test | Lucid Diligence Brief
This Lucid Diligence Brief examines Basecamp Research’s $140M Series C and…
Rare Diseases Strategic Roundup: From Approval To Access | Aug 12 - Sep 16, 2026
Rare Disease Strategic Roundup exploring Developments and Competitive Shifts…
Cell and Gene Therapy Strategic Roundup | Jul 29 – Aug 31, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
Genprex and Roche Diagnostics begin TROP2 assay validation to support…
Cell and Gene Therapy Strategic Roundup | June 24–July 29, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Sickle Cell Gene Therapies Ranked by AI Models | LucidScope AI Visibility Audit
Key Findings from the LucidScope AI Visibility Audit of Casgevy, Lyfgenia,…
Public Health Today—June 12, 2026
This weekly public health update highlights major developments across…
FSCDR 2026 Preview: Competitive Shifts in Sickle Cell Disease
FSCDR 2026 at a glance FSCDR 2026 will examine how sickle cell disease (SCD)…
Lucid Diligence Brief: Genethon and Ampersand Biomedicines AAV Partnership
Lucid Diligence Brief: Genethon and Ampersand Biomedicines partner to design…
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic…